Recuro Health, a digital health solutions startup aiming to shift U.S. healthcare from reactive to proactive care, has closed a $47 M Series B financing round led by ARCH Venture Partners, Flippen Group, GPG Ventures, 4D Capital and others
The new capital will be used to expand its “Digital Medical Home” model—offering virtual primary care, behavioral health, at‑home lab testing and genomics—integrating advanced diagnostics and targeted cancer-screening tools to support proactive clinical workflows
Michael Gorton, CEO and founder, stated:
“The continued support of our investors is a clear sign of their confidence in our mission… committed to building upon the success of our Digital Medical Home and continuing to advance the next generation of digital care services.”
Robert Nelsen of ARCH added that Recuro is “best of breed in the intersection of science, diagnostics and digital health,” and praised its ability to respond to market shifts and close gaps in care
Founded in 2021, Recuro’s services—covering virtual primary and urgent care, behavioral health, at-home lab testing and genomics—are now used by millions nationwide
The company aims to integrate data analytics, care navigation, quality services and guided referrals into a unified virtual-first platform, striving to reduce costs, improve outcomes, and replace fragmented PDF-based records with real-time patient data
New venture capital firm to create and invest in early-stage healthcare companies applying novel technologies to frontier biology and redefine patient care
Radiopharmaceuticals are emerging as the future of cancer care, combining targeted precision with powerful radiation to deliver safer, more effective treatments.
Join us in building the future of medicine through innovative technology and biology convergence
